The FDA approved orforglipron, a once-daily pill that works like Ozempic and Wegovy but doesn't require injections. The oral medication helps people lose 5-10% of their body weight and lowers blood sugar levels without fasting requirements.
Posts published in “GLP-1”
The GLP-1 medication market is seeing significant changes, including FDA approval of oral weight loss drugs and expanded Medicare coverage starting in July 2024. These shifts could make weight loss medications more accessible to patients.
The growing peptide market is creating competition for brand-name GLP-1 drugs as compounding pharmacies offer alternatives to expensive medications. This trend is causing tension between commercial drug companies and compounding pharmacies over patient access to weight loss treatments.
Natural GLP-1 hormone levels from eating regular foods have little effect on appetite or weight loss, according to researchers. The much higher hormone levels achieved through medications like Ozempic are what actually reduce hunger and help with weight loss.
Some patients taking GLP-1 medications for weight loss report experiencing less pleasure and excitement in their daily lives. This potential mental health side effect is raising concerns among doctors and patients about the emotional impact of these popular weight loss drugs.
Some people taking GLP-1 weight loss drugs like Ozempic and Wegovy say they feel less pleasure and excitement in daily life. Doctors confirm these emotional changes are real side effects, not imagined, and advise patients to seek help if they experience reduced joy.
About 80% of employer health plans don't cover GLP-1 medications like Wegovy for weight loss, though some companies are adding coverage hoping it will reduce long-term healthcare costs. Only about 20% of employers currently offer this benefit to their workers.
A local news investigation examines the benefits and potential risks of popular GLP-1 medications like Ozempic and Wegovy, featuring patient experiences including one woman who has used the treatment for two years.